Kenneth G. Shelburne Mann

Kenneth G. Shelburne Mann's AcademicInfluence.com Rankings

Philosophy

#3094

World Rank

#5078

Historical Rank

Logic

#945

World Rank

#1540

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Kenneth G. Shelburne Mann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth G. Shelburne Mann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Evidence of estrogen receptors in normal human osteoblast-like cells (1988) (822)
What is all that thrombin for? (2003) (535)
The dynamics of thrombin formation. (2003) (513)
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. (1979) (512)
Surface-dependent reactions of the vitamin K-dependent enzyme complexes (1990) (493)
Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. (1988) (490)
Platelet function monitoring in patients with coronary artery disease. (2007) (488)
Evidence of estrogen receptors in normal human osteoblast-like cells. (1988) (485)
Surface-dependent reactions of the vitamin K-dependent enzyme complexes. (1990) (429)
The estimation of polypeptide chain molecular weights by gel filtration in 6 M guanidine hydrochloride. (1969) (425)
The mechanism of inactivation of human factor V and human factor Va by activated protein C. (1994) (411)
Complete cDNA and derived amino acid sequence of human factor V. (1987) (409)
Blood clotting in minimally altered whole blood. (1996) (404)
A Model for the Stoichiometric Regulation of Blood Coagulation* (2002) (387)
"Normal" thrombin generation. (1999) (387)
Thrombin functions during tissue factor-induced blood coagulation. (2002) (383)
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. (1983) (350)
Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. (2009) (320)
Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins. (1986) (303)
A model for the tissue factor pathway to thrombin. I. An empirical study. (1994) (286)
Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. (1988) (276)
Tissue factor activity in whole blood. (2005) (275)
Radioimmunoassay of factor V in human plasma and platelets. (1982) (273)
Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. (1988) (258)
Characterization of the Molecular Defect in Factor VR506A(*) (1995) (252)
Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation (2001) (251)
A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa. (2003) (244)
Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. (1995) (244)
Statins and Blood Coagulation (2004) (242)
Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. (1987) (237)
Factor V: a combination of Dr Jekyll and Mr Hyde. (2003) (229)
Bone loss and reduced osteoblast function in primary biliary cirrhosis. (1985) (226)
Thrombin formation. (2003) (223)
Mechanism of factor VIIa-dependent coagulation in hemophilia blood. (2002) (220)
Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography (2005) (220)
Effect of renal function on plasma levels of bone Gla-protein. (1983) (217)
Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. (1976) (213)
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. (2007) (213)
Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* (1997) (206)
Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. (1983) (204)
Blood coagulation in hemophilia A and hemophilia C. (1998) (196)
Isolation and characterization of native adult osteonectin. (1985) (184)
Chemical and physical properties of aequorin and the green fluorescent protein isolated from Aequorea forskålea. (1978) (184)
Isolation of functional human coagulation factor V by using a hybridoma antibody. (1981) (184)
A model for the tissue factor pathway to thrombin. II. A mathematical simulation. (1994) (183)
Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. (1985) (182)
Coordinate binding of factor Va and factor Xa to the unstimulated platelet. (1981) (179)
Differentiation of metal ion-induced transitions of prothrombin fragment 1. (1977) (179)
Thrombin-catalyzed activation of single chain bovine factor V. (1979) (175)
Aspirin Alters the Cardioprotective Effects of the Factor XIII Val34Leu Polymorphism (2003) (172)
Isolation and study of an acquired inhibitor of human coagulation factor V. (1986) (170)
Surface-dependent hemostasis. (1992) (168)
Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. (1999) (164)
Activation/inactivation of human factor V by plasmin. (1989) (163)
PlA2 Polymorphism of &bgr;3 Integrins Is Associated With Enhanced Thrombin Generation and Impaired Antithrombotic Action of Aspirin at the Site of Microvascular Injury (2001) (162)
Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. (1979) (160)
Comparison of the inhibition of thrombin by three plasma protease inhibitors. (1978) (155)
Tissue factor in coagulation: Which? Where? When? (2009) (146)
Bone gla protein (osteocalcin) assay standardization report (1990) (145)
Preparation and partial characterization of two forms of bovine thrombin. (1975) (144)
Isolation and characterization of single chain bovine factor V. (1979) (143)
The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. (1983) (143)
Thrombin generation profiles in deep venous thrombosis (2005) (143)
Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. (1991) (142)
Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. (1993) (142)
Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. (1973) (142)
The isomorphous structures of prethrombin2, hirugen–, and PPACK–thrombin: Changes accompanying activation and exosite binding to thrombin (1994) (141)
Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases* (1997) (141)
PHYSIOCHEMICAL AND BIOLOGICAL PROPERTIES OF THE MAJOR BASIC PROTEIN FROM GUINEA PIG EOSINOPHIL GRANULES (1974) (141)
Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. (2012) (139)
Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. (1984) (139)
The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function (2004) (139)
Human platelets contain and secrete osteonectin, a major protein of mineralized bone. (1986) (138)
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. (2000) (137)
Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. (1988) (137)
Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. (1983) (136)
Intracellular and Surface Distribution of Monocyte Tissue Factor: Application to Intersubject Variability (2005) (135)
Interaction of coagulation factor V and factor Va with platelets. (1979) (132)
The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. (1986) (132)
Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation (1997) (131)
The factor Xa-catalyzed activation of factor V. (1983) (130)
Primary structure of human prethrombin 2 and alpha-thrombin. (1977) (130)
Phospholipid-binding properties of bovine factor V and factor Va. (1979) (130)
Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. (1984) (130)
Role of the membrane surface in the activation of human coagulation factor X. (1992) (128)
Citrate anticoagulation and the dynamics of thrombin generation (2007) (126)
Identification of a thrombin sequence with growth factor activity on macrophages. (1986) (125)
An Integrated Study of Fibrinogen during Blood Coagulation* (1999) (124)
Chemistry and biology of thrombin (1977) (124)
The regulation of clotting factors. (1997) (124)
Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. (1982) (122)
Prothrombin fragments. Ca2+ binding and activation kinetics. (1975) (119)
Expression of human bone-related proteins in the hematopoietic microenvironment. (1990) (117)
Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. (1994) (117)
Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. (1996) (116)
"Clotspeed," a mathematical simulation of the functional properties of prothrombinase. (1984) (113)
Models of blood coagulation (2000) (112)
Single-chain nature of human serum transferrin. (1970) (112)
Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C* (2001) (107)
Overview of Hemostasis (2014) (107)
Differential effects of anticoagulants on the activation of platelets ex vivo. (1997) (107)
Cofactor dependence of factor Xa incorporation into the prothrombinase complex. (1981) (106)
The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. (1985) (106)
Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. (1998) (105)
Growth on type I collagen promotes expression of the osteoblastic phenotype in human osteosarcoma MG‐63 cells (1992) (105)
Heterogeneity of human bone (1990) (104)
Kinetics of human factor VII activation. (1996) (104)
Human prothrombin activation. (1975) (102)
Multiple active forms of thrombin. IV. Relative activities of meizothrombins. (1990) (102)
The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation. (1973) (102)
Tumor cell generation of thrombin via functional prothrombinase assembly. (1985) (102)
The Tissue Factor Requirement in Blood Coagulation* (2005) (101)
Comparison of monoclonal and polyclonal antibody‐based immunoassays for osteocalcin: A study of sources of variation in assay results (1990) (99)
The resuscitative fluid you choose may potentiate bleeding. (2006) (98)
Metal ion induced conformational transitions of prothrombin and prothrombin fragment 1. (1978) (97)
Clotting factor deficiency in early trauma-associated coagulopathy. (2011) (96)
Role of the membrane in the inactivation of factor Va by activated protein C. (1993) (95)
Active tissue factor in blood? (2004) (94)
The Mechanism of Inactivation of Human Platelet Factor Va from Normal and Activated Protein C-resistant Individuals (*) (1995) (94)
FLUORESCENCE STUDIES OF THE BINDING OF FACTOR Va TO PHOSPHOLIPID VESICLES (1988) (93)
The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. (1982) (91)
Protein polypeptide chain molecular weights by gel chromatography in guanidinium chloride. (1972) (91)
Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. (2001) (91)
Thrombin generation: phenotypic quantitation (2004) (90)
Antiplatelet agents in tissue factor-induced blood coagulation. (2001) (90)
The assembly of blood clotting complexes on membranes (1987) (89)
The role of the tissue factor pathway in initiation of coagulation. (1998) (87)
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). (1997) (87)
A review of the therapeutic uses of thrombin (2004) (86)
The plasma hemostatic proteome: thrombin generation in healthy individuals (2005) (86)
Zymogen/enzyme discrimination using peptide chloromethyl ketones. (1989) (86)
Structure of human osteonectin based upon analysis of cDNA and genomic sequences. (1989) (85)
Prothrombinase complex assembly on the platelet surface is mediated through the 74,000-dalton component of factor Va. (1983) (82)
The evaluation of complex-dependent alterations in human factor VIIa. (1992) (82)
The role of the red cell membrane in thrombin generation. (2013) (79)
The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes (1994) (77)
The binding of activated protein C to factors V and Va. (1986) (75)
Activated Protein C Cleavage of Factor Va Leads to Dissociation of the A2 Domain* (1997) (75)
The collagen binding specificity of bone and platelet osteonectin is related to differences in glycosylation. (1991) (74)
Factor XIa and tissue factor activity in patients with coronary artery disease (2007) (74)
Localization of a chemotactic domain in human thrombin. (1984) (74)
Characterization of Factor V activation intermediates. (1984) (73)
A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo (1988) (73)
Assembly of the prothrombinase complex in the absence of prothrombin. (1981) (73)
The Significance of Circulating Factor IXa in Blood* (2004) (73)
[21] Factor V (1981) (72)
Structural studies on bovine lactoferrin. (1970) (71)
The complete cDNA sequence of bovine coagulation factor V. (1992) (71)
Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. (1980) (68)
The impact of uncertainty in a blood coagulation model. (2009) (67)
Systemic blood coagulation activation in acute coronary syndromes. (2009) (67)
Thrombin generation in hemorrhage control and vascular occlusion. (2011) (67)
Phosphorylation of factor Va and factor VIIIa by activated platelets. (1993) (66)
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid (2014) (65)
Discordant fibrin formation in hemophilia (2009) (65)
Platelet coagulation factor Va: the major secretory platelet phosphoprotein. (1994) (65)
Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN * (1997) (65)
Osteonectin in matrix remodeling. A plasminogen-osteonectin-collagen complex. (1994) (65)
Coagulation Factor V contains copper ion. (1984) (65)
Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. (1997) (64)
No evidence for tissue factor on platelets. (2010) (64)
Characterization of human osteoblast and megakaryocyte-derived osteonectin (SPARC). (1992) (64)
Effect of acute increases in bone matrix degradation on circulating levels of bone‐gla protein (1986) (63)
The Factor V Activation Paradox* (2004) (62)
Influence of Factor VIIa and Phospholipids on Coagulation in “Acquired” Hemophilia (2003) (62)
Prothrombin activation. (1974) (61)
The kinetics and cofactor dependence of the two cleavages involved in prothrombin activation. (1983) (60)
The activation of prothrombin. I. Isolation and preliminary characterization of intermediates. (1973) (59)
Synthesis of coagulation factor V by cultured aortic endothelium. (1984) (59)
Thrombin generation and cell‐dependent hypercoagulability in sickle cell disease (2016) (58)
Oral Anticoagulation Thresholds (2001) (58)
Defining the Boundaries of Normal Thrombin Generation: Investigations into Hemostasis (2012) (58)
Phagocytosis in human platelets: localization of acid phosphatase-positive phagosomes following latex uptake. (1976) (57)
Prothrombin Activation by Platelet-associated Prothrombinase Proceeds through the Prethrombin-2 Pathway via a Concerted Mechanism* (2012) (57)
Substitution of lanthanide ions for calcium ions in the activation of bovine prothrombin by activated factor X. High affinity metal-binding sites of prothrombin and the derivatives of prothrombin activation. (1976) (56)
The association of coagulation factor Xa and factor Va. (1991) (55)
1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women. (1987) (55)
Blood coagulation dynamics in haemostasis (2009) (55)
Purification of porcine and human ristocetin-Willebrand factor. (1977) (55)
The reassociation of factor Va from its isolated subunits. (1989) (55)
Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders. (1987) (54)
Quantitation of anti-factor VIII antibodies in human plasma. (2009) (54)
Synthesis of coagulation factor V by cultured aortic endothelium (1984) (54)
Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. (1996) (54)
Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. (2005) (53)
Thrombin generation and bleeding in haemophilia A (2009) (53)
Structural Requirements for Expression of Factor Va Activity* (2003) (53)
Coagulation procofactor activation by factor XIa (2010) (52)
Immunolocalization of noncollagenous bone matrix proteins in lumbar vertebrae from intact and surgically menopausal cynomolgus monkeys (1993) (52)
INACTIVATION OF FACTOR Va BY PIASMIN (1987) (52)
Factor V is a substrate for the transamidase factor XIIIa. (1986) (52)
Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets. (1993) (51)
Prothrombin (1963) (51)
Thrombin generation in rheumatoid arthritis: Dependence on plasma factor composition (2010) (51)
The effect of Arg306 → Ala and Arg506 → Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S (1997) (51)
Models of blood coagulation. (2006) (50)
Factor Va-membrane interaction is mediated by two regions located on the light chain of the cofactor. (1994) (50)
Multiple active forms of thrombin. II. Mechanism of production from prothrombin. (1971) (49)
Molecular weight of undegraded plasma factor V. (1981) (49)
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. (2000) (49)
THE ROLE OF FACTOR V IN THE ASSEMBLY OF THE PROTHROMBINASE COMPLEX * (1981) (48)
Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. (1990) (48)
Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin. (1986) (48)
The assembly of the prothrombinase complex on adherent platelets. (1993) (48)
Factor V Quebec revisited. (1996) (48)
Assembly of prothrombinase complex. (1993) (48)
Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. (1984) (47)
Characteristics of the association between prothrombin fragment 2 and alpha-thrombin. (1976) (47)
Platelet factor Xa receptor. (1992) (47)
The Nature of the Stable Blood Clot Procoagulant Activities* (2008) (47)
Contribution of the heavy and light chains of factor Va to the interaction with factor Xa. (1994) (47)
Epitopes of the human erythrocyte Ca2+-Mg2+ ATPase pump in human osteoblast-like cell plasma membranes. (1988) (46)
Mechanisms of thrombus formation and lysis. (1988) (46)
Blood coagulation. (2002) (46)
Synthetic substrates for human factor VIIa and factor VIIa-tissue factor. (1993) (46)
Isolation and characterization of an acquired antithrombin antibody. (1990) (45)
Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. (1995) (45)
A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. (1999) (45)
Multiple active forms of thrombin. I. Partial resolution, differential activities, and sequential formation. (1971) (45)
Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cysteine for arginine-382. (1988) (44)
Introduction: blood coagulation. (1993) (43)
Thrombin: can't live without it; probably die from it. (2003) (43)
α-Thrombin Stimulates Urokinase Production and DNA Synthesis in Cultured Human Cerebral Microvascular Endothelial Cells (1995) (42)
Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. (1997) (42)
Proteolytic alterations of factor Va bound to platelets. (1983) (42)
Immunochemical studies of conformational alterations in bone gamma-carboxyglutamic acid containing protein. (1984) (42)
Cultured aortic endothelial cells from pigs with von Willebrand disease: in vitro model for studying the molecular defect(s) of the disease. (1977) (42)
Assembly of the prothrombinase complex. (1982) (41)
Determination of the disulfide bridges in factor Va heavy chain. (1993) (41)
Extrinsic pathway proteolytic activity. (1993) (41)
Evidence that meizothrombin is an intermediate product in the clotting of whole blood. (1995) (40)
A monoclonal antibody which inhibits the factor Va:factor Xa interaction. (1983) (40)
Prothrombin Quick. A newly identified dysprothrombinemia. (1978) (40)
Multiple active forms of thrombin. 3. Polypeptide chain location of active site serine and carbohydrate. (1973) (40)
The calcium-binding properties of bovine factor V. (1980) (39)
Tissue factor activity and function in blood coagulation. (2008) (38)
Identification of the noncollagenous proteins of bovine bone by two-dimensional gel electrophoresis (1984) (38)
Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. (1990) (38)
Electrostatic and hydrophobic interactions are involved in factor Va binding to membranes containing acidic phospholipids. (1994) (38)
The function of factor XI in tissue factor‐initiated thrombin generation (2003) (38)
Cooperative interaction of divalent metal ions, substrate, and tissue factor with factor VIIa. (1994) (37)
Bone marrow accessory cells regulate human bone precursor cell development. (2000) (37)
Tissue factor in thrombosis and hemorrhage. (2007) (36)
Factor VLeiden and thrombophilia. (1997) (36)
Carbohydrates and Activity of Natural and Recombinant Tissue Factor* (2009) (36)
Does the genotype predict the phenotype? Evaluations of the hemostatic proteome (2004) (35)
The Prothrombotic Phenotypes in Familial Protein C Deficiency Are Differentiated by Computational Modeling of Thrombin Generation (2012) (35)
Molecular weight and subunit structure of yeast enolase. (1970) (35)
Identification and characterization of a phospholipid-binding site of bovine factor Va. (1990) (34)
The Role of the Membrane in the Inactivation of Factor Va by Plasmin (2001) (34)
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. (2012) (34)
Novel, Bedside, Tissue Factor–Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy (2000) (33)
Decarboxylation of bovine prothrombin fragment 1 and prothrombin. (1979) (33)
Lipid mobility in the assembly and expression of the activity of the prothrombinase complex. (1985) (32)
Empirical and theoretical phenotypic discrimination (2009) (32)
The activation of bovine protein C by factor Xa. (1989) (32)
Monoclonal antibodies to native noncollagenous bone-specific proteins. (1984) (32)
The osteonectin family of proteins. (1988) (32)
Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. (1989) (32)
Growth‐promoting effects of esterolytically inactive thrombin on macrophages (1986) (32)
The isolation of human platelet factor V. (1987) (31)
High-pressure liquid chromatographic analysis of amino acid phenylthiohydantoins: comparison with other techniques. (1976) (31)
The role of the membrane in the expression of the vitamin K-dependent enzymes. (1992) (31)
Structure of membrane‐bound human factor Va (1994) (31)
A conserved epitope on several human vitamin K-dependent proteins. Location of the antigenic site and influence of metal ions on antibody binding. (1988) (30)
Identification of a congenital dysthrombin, thrombin Quick. (1980) (30)
Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk. (1989) (30)
Dilutional control of prothrombin activation at physiologically relevant shear rates. (2011) (30)
Factor Xa Generation by Computational Modeling: An Additional Discriminator to Thrombin Generation Evaluation (2012) (30)
Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. (2011) (29)
Alloantibodies to factor VIII in haemophilia (2011) (29)
Surface‐Dependent Reactions in the Propagation Phase of Blood Coagulation (1991) (29)
Anticoagulants and the Propagation Phase of Thrombin Generation (2011) (29)
The coagulation explosion. (1994) (29)
Aminonaphthalenesulfonamides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes. (1992) (28)
The preparation and activation of (sialyl-3H)prothrombin. (1974) (27)
Cellular regulation of blood coagulation: a model for venous stasis. (2010) (27)
Multiple Active Forms of Thrombin (2001) (27)
A membrane-mediated catalytic event in prothrombin activation. (1994) (26)
The molecular weights of bovine thrombin and its primary autolysis products. (1969) (26)
Modeling thrombin generation: plasma composition based approach (2013) (25)
Internal duplication and sequence homology in factors V and VIII. (1985) (25)
Monoclonal antibodies to human coagulation factor V and factor Va (1983) (25)
Human platelet osteonectin: release, surface expression, and partial characterization (1990) (25)
The "normal" factor VIII concentration in plasma. (2010) (25)
Subunits of rat liver mitochondrial malate dehydrogenase. (1969) (24)
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management (2006) (24)
Progressive development of a thrombin inhibitor binding site. (1982) (24)
Factor VIII therapy for hemophilia A: current and future issues (2014) (24)
[13] Factor V (1993) (24)
Effects of an acidic environment on coagulation dynamics (2016) (23)
Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients. (1988) (23)
Evidence for a common metal ion-dependent transition in the 4-carboxyglutamic acid domains of several vitamin K-dependent proteins. (1989) (23)
Identification of human megakaryocyte coagulation factor V. (1985) (23)
Thrombolytic therapy and proteolysis of factor V. (1997) (23)
Validation of the bone gla protein (osteocalcin) assay (1990) (23)
Thromboelastography as a Better Indicator of Postinjury Hypercoagulable State Than Prothrombin Time or Activated Partial Thromboplastin Time (2012) (22)
A rapid technique for the preparation of factor V deficient plasma. (1979) (22)
The interaction of bone Gla protein (osteocalcin) with phospholipid vesicles. (1989) (22)
Studies on the subunit molecular weight of beef heart lactate dehydrogenase. (1972) (22)
Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation. (1979) (21)
On the reaction of purified bovine thrombin with N-acetylimidazole. (1973) (21)
The activation of prothrombin. 3. The partial amino acid sequences at the amino terminal of prothrombin and the intermediates of activation. (1973) (21)
Mathematical simulation of prothrombinase. (1992) (21)
Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events (2012) (21)
Age-related phenotypic alterations in populations of purified human bone precursor cells. (1999) (21)
In-depth analysis of clotting dynamics in burn patients. (2016) (21)
Differentiation of enzyme and substrate binding in the prothrombinase complex. (1983) (21)
Potency and mass of factor VIII in FVIII products (2009) (21)
Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis. (1999) (20)
Active site-specific immunoassays. (1990) (20)
Hypothermia and hemostasis in severe trauma: A new crossroads workshop report (2012) (20)
Report of the ad Hoc committee on nomenclature and standards for bone proteins and growth factors (1986) (20)
Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. (2010) (20)
Platelets do not express the oxidized or reduced forms of tissue factor. (2014) (20)
Human d-Phe-Pro-Arg-CH2-α-thrombin crystallization and diffraction data (1989) (20)
Continuous thrombin generation in whole blood: New applications for assessing activators and inhibitors of coagulation. (2016) (20)
The challenge of regulating anticoagulant drugs: focus on warfarin. (2005) (20)
Thrombosis: theoretical considerations. (1997) (19)
The Coagulation Explosion a (1994) (19)
The purification and properties of bovine thrombin. (1970) (19)
Monoclonal antibodies selective for the functional states of bovine factor V and factor Va. (1982) (19)
Insights into the complex association of bovine factor Va with acidic-lipid-containing synthetic membranes. (1996) (19)
Studies on the measurement of protein S in plasma. (1991) (18)
Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. (1995) (18)
Microparticles formed during storage of red blood cell units support thrombin generation (2017) (18)
Studies on IgA and IgA monoclonal proteins derived from a single patient. Evidence for identical light chains and variable regions of the heavy chain. (1975) (18)
Membrane Binding Events in the Initiation and Propagation Phases of Tissue Factor-initiated Zymogen Activation under Flow* (2011) (18)
A simple purification of human factor X using a high affinity monoclonal antibody immunoadsorbant. (1985) (18)
Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation. (2012) (17)
The covalent differences between bovine alpha- and beta-thrombin. A structural explanation for the changes in catalytic activity. (1979) (17)
Structural model of factors V and Va based on scanning transmission electron microscope images and mass analysis. (1990) (17)
Bovine alpha- and beta-thrombin. Reduced fibrinogen-clotting activity of beta-thrombin is not a consequence of reduced affinity for fibrinogen. (1984) (17)
Prothrombin domains: circular dichroic evidence for a lack of cooperativity. (1979) (17)
Modeling of human factor Va inactivation by activated protein C (2012) (17)
Evidence that the thrombin-catalyzed feedback cleavage of fragment 1.2 at Arg154-Ser155 promotes the release of thrombin from the catalytic surface during the activation of bovine prothrombin. (1988) (17)
Interchangeability of rotational elastographic instruments and reagents (2014) (17)
Membrane penetration of bovine factor V and Va detected by labeling with 5-iodonaphthalene-1-azide. (1987) (16)
Nature of the isozymes of rat liver mitochondrial malate dehydrogenase. (1968) (16)
The effect of high circulating estradiol levels on thrombin generation during in vitro fertilization. (2009) (16)
Influence of bivalirudin on tissue factor-triggered coagulation (2007) (16)
Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q-wave myocardial infarction (1994) (16)
Activated factor XI and tissue factor in inflammatory bowel disease. (2010) (15)
A monoclonal-antibody-based radioimmunoassay for measurement of protein C in plasma. (1988) (15)
Human platelet osteonectin: release, surface expression, and partial characterization. (1990) (15)
Studies on the structure of bovine factor V by scanning transmission electron microscopy. (1985) (15)
TACTIC: Trans‐Agency Consortium for Trauma‐Induced Coagulopathy (2015) (15)
Discrimination of normal and abnormal prothrombin and protein C in plasma using a calcium ion-inhibited monoclonal antibody to a common epitope on several vitamin K-dependent proteins. (1989) (15)
Stability of porcine factor VIII. (1975) (15)
Ristocetin-induced aggregation of gel filtered platelets a study of von Willebrand's disease and the effect of aspirin (1973) (15)
The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial (2004) (15)
Membrane-bound enzyme complexes in blood coagulation. (1984) (15)
The biochemistry of coagulation. (1984) (14)
Stroma free human platelet lysates potentiate the in vivo thrombogenicity of factor Xa by the provision of coagulant‐active phospholipid (1982) (14)
Improve high-pressure liquid chromatographic separation of amino acid phenylthiohydantoins (1978) (14)
Factor V: Dr. Jeckyll and Mr. Hyde. (2001) (14)
Rivaroxaban Delivery and Reversal at a Venous Flow Rate (2012) (14)
Monoclonal antibodies to human coagulation factor V and factor Va. (1983) (14)
Detection of procollagen biosynthesis using peptide-specific antibodies. (1990) (13)
Regulation and regulatory role of gamma-carboxyglutamic acid containing clotting factors. (1996) (13)
Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest (1994) (13)
Self-association of human protein S. (2000) (13)
Blood Coagulation (2004) (13)
Monoclonal antibodies selective for activated Factor V. Immunochemical probes for structural transitions occurring during the thrombin-catalyzed activation of the procofactor. (1983) (13)
An inhibitory monoclonal antibody to factor X that blocks prothrombin activation but not prothrombinase enzyme assembly. (1988) (13)
Disulfide reduction abolishes tissue factor cofactor function. (2013) (12)
Chemical and physical studies on the structure of Escherichia coli elongation factor G. (1975) (12)
Variability in plasma prothrombin concentration: implications for use in epidemiology (1998) (12)
Quantitation of human in vitro megakaryocytopoiesis by radioimmunoassay. (1987) (12)
Alpha-thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. (1995) (12)
Effect of polylysine on the activation of prothrombin. Polylysine substitutes for calcium ions and factor V in the factor Xa catalyzed activation of prothrombin. (1976) (12)
CFU-M-derived human megakaryocytes synthesize glycoproteins IIb and IIIa. (1986) (12)
CHAPTER 19 – Interactions Between Platelets and the Coagulation System (2007) (11)
Analysis of tissue plasminogen activator specificity using peptidyl fluorogenic substrates. (1997) (11)
Isolation of human platelet and red blood cell plasma membrane proteins by preparative detergent electrophoresis. (1979) (11)
Isozymes of rat liver mitochondrial malate dehydrogenase. Evidence for the existence of nonidentical subunits. (1970) (11)
Fluorogenic substrates for activated protein C: substrate structure-efficiency correlation. (1995) (11)
Determination of the disulfide bridges in factor Va light chain. (1993) (11)
Activation of fluorescein-labeled prothrombin. (1973) (11)
Ultrastructural cytochemistry of platelets and megakaryocytes in the carcinoid syndrome. (1976) (11)
Warfarin and the biochemistry of the vitamin K dependent proteins. (1987) (10)
Factor VII-activating protease: coagulation, fibrinolysis, and atherothrombosis? (2003) (10)
From Principle to Practice: Bridging the Gap in Patient Profiling (2013) (10)
The mechanism of activation of rabbit plasminogen by urokinase. Lack of a preactivation peptide. (1974) (10)
Posttranslational modifications of tissue factor. (2012) (10)
Tissue factor controversies. (2012) (10)
Identification of an inactivating cleavage site for α-thrombin on the heavy chain of factor Va (2007) (10)
Adding the vessel wall to Virchow's triad (2006) (10)
Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates. (2017) (10)
Intermediates of prothrombin activation. (1973) (9)
Differences in the fractional abundances of carbohydrates of natural and recombinant human tissue factor. (2011) (9)
Loss of membrane-dependent factor Va cleavage: a mechanistic interpretation of the pathology of protein CVermont (1994) (9)
Peptide chloromethyl ketones as labeling reagents. (1993) (9)
Immunochemical relationships of the intermediates of prothrombin activation. (1975) (8)
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. (1998) (8)
Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction (2005) (8)
Factor V: a prototype pro-cofactor for vitamin K-dependent enzyme complexes in blood clotting. (1989) (8)
Monoclonal antibodies to human vitamin K-dependent protein S (1986) (8)
Factor V turnover in a primate model. (1995) (8)
A dual beam total internal reflection fluorescence spectrometer for dynamic depth resolved measurements of biochemical liquid‐solid interface binding reactions in opaque solvents (1991) (8)
Loss of membrane-dependent factor Va cleavage: a mechanistic interpretation of the pathology of protein CVermont. (1994) (7)
Factor V Leiden and thrombophilia. (1995) (7)
Antigenic changes produced by complex formation between thrombin and antithrombin-III. (1981) (7)
Molecular Basis of Blood Coagulation (2018) (7)
Posttranslational modifications and activity of natural and recombinant tissue factor. (2010) (7)
The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood: comment (2015) (7)
Assessment of Coagulation Homeostasis in Blunt, Penetrating, and Thermal Trauma: Guidance for a Multicenter Systems Biology Approach (2019) (6)
Factor V. (1981) (6)
Potential analytes for the diagnosis of thrombosis. An overview. (1992) (6)
Activation, activity and inactivation of factor VIII in factor VIII products (2016) (6)
Blood coagulation : Molecular mechanisms underlying alcohol-induced cardioprotection : contribution of hemostatic components (1999) (6)
5 Mechanisms of vitamin K antagonism (1990) (6)
Response: Mechanism of Action of High-Dose Factor VIIa (2003) (6)
Absence of Dimers and Nature of Iron Binding in Transferrin Solutions (1970) (6)
Dynamic Nature of Thrombin Generation, Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction Fibrin (1995) (5)
A Molecular Model of the Human Prothrombinase Complex (2008) (5)
Megakaryocyte colony growth‐supporting activities in human plasma: Modification by platelets and platelet membranes (1987) (5)
Immunohistochemical Method for the Simultaneous Demonstration of Three Proteins in EDTA Decalcified Paraffin Embedded Bone Sections (1992) (5)
Polypeptide Chain Molecular Weight Determination by Gel Permeation Studies on Agarose Columns in 6MGuanidinium Chloride (1973) (5)
Early abnormal fibrinolysis and mortality in patients with thermal injury: a prospective cohort study. (2021) (5)
Monoclonal antibodies to human vitamin K-dependent protein S. (1986) (5)
Analysis of factor XIa, factor IXa and tissue factor activity in burn patients. (2017) (5)
Quantitation of Natural, Recombinant, Cell-Surface and Plasma Tissue Factor. (2004) (4)
Active site-specific assays for enzymes of coagulation and fibrinolytic pathways. (1993) (4)
Identification and isolation of vitamin K-dependent proteins by HPLC. (1986) (4)
Hypercoagulability in Sickle Cell Disease: The Importance of the Cellular Component of Blood (2014) (4)
THE COMPLETE AMINO ACID SEQUENCE OF HUMAN FACTOR V (1987) (4)
Issues complicating precision dosing for factor VIII prophylaxis. (2018) (4)
Analyses of protein S function. (2005) (4)
Quantitation of Non-Inhibitory Anti-Factor VIII Antibodies in human Plasma (2008) (4)
Identification of a vitamin D-responsive protein on the surface of human osteosarcoma cells. (1989) (4)
Distribution of prothrombin carbohydrate units upon thrombin activation. (1975) (4)
The Nature of LPS-Stimulated Monocyte Tissue Factor Activity (2008) (3)
Membrane-Bound and Soluble Tissue Factor - Fuse and Fire Extinguisher. (2004) (3)
Endogenous Procoagulant Activity in Trauma Patients and Its Relationship to Trauma Severity (2019) (3)
College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Future Directions (1998) (3)
Prothrombinase formation at the site of microvascular injury and aspirin resistance: the effect of simvastatin. (2010) (3)
The nature of lipopolysaccharide-stimulated monocyte tissue factor activity. (2013) (2)
Simulating blood coagulation: the contribution of α2‐macroglobulin and α1‐antitrypsin (2006) (2)
Blood coagulation at the site of microvascular injury in healthy and coumadin-treated subjects heterogenous for factor V Leiden mutation (2007) (2)
Hemodilution and Endothelial Cell Regulation of Whole Blood Coagulation. (2018) (2)
P14. Circadian changes in bone turnover assessed by serum bone gla-protein and urinary deoxypyridinoline: effect of growth and ageing (1990) (2)
Inhalation Injury Is Associated With Endotheliopathy and Abnormal Fibrinolytic Phenotypes in Burn Patients: A Cohort Study (2021) (2)
Mammalian blood coagulation factors and inhibitors (1993) (2)
The Conversion of Prothrombin into Thrombin (1975) (2)
Factor XI Activation In Tissue Factor-Initiated Blood Coagulation (2011) (2)
Monoclonal antibodies and coagulation (1985) (2)
Calcium and prothrombin activation. (1974) (2)
Proliferation and Maturation of Human Megakaryocytes in Vitro (1987) (2)
Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir (2021) (2)
Chapter 1. Overview of Hemostasis (2007) (2)
Erratum to "Tissue factor controversies" [Thrombosis Research 129 (2012) S5–S7] (2012) (2)
Tissue Factor Structure and Coagulation (2015) (2)
Thrombin: structural features related to specificity. (1977) (2)
Allosteric Cysteine Oxidation Does Not Play a Role in Tissue Factor Decryption (2011) (2)
Taking the thrombin "fork". (2010) (2)
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy : Future directions : Laboratory monitoring of anticoagulant therapy (1998) (2)
Real human tissue factor (2006) (2)
Demystifying Tissue Factor. (2004) (2)
Ultrastructural characteristics of dog and human platelets adherent to native and collagen-coupled cuprophan. (2008) (1)
Hemophilia and the Dynamics of Hemostasis. (2005) (1)
Mechanisms of vitamin K antagonism. (1990) (1)
Citrate Blood a Century of Artifact. (2006) (1)
Molecular and Cellular Hemostasis and Fibrinolysis (2002) (1)
Changes in Fibrinogen After rt-PA Administration (1996) (1)
Identification of an inactivating cleavage site for alpha-thrombin on the heavy chain of factor Va. (2007) (1)
Alazzl-to-Val Substitution Results in Reduced Cofactor Activity (2002) (1)
The effects of flow on the activation of bovine prothrombin by prothrombinase at physiologically relevant shear rates (2010) (1)
Blood coagulation: link between thrombosis and atherosclerosis, an overview (1994) (1)
Analysis of the Protein C System Under Flow and the Impact of Red Blood Cells (2014) (1)
Butenas et al Tissue Factor in Coagulation : Which ? Where ? When ? 1991 (2009) (1)
Neutralizing and Non-Neutralizing Anti-FVIII Antibodies in Black and White Hemophilia A Subjects: A Natural History Profile (2019) (1)
Coagulation inhibitor values in myocardial infarction compared to those in normals (1991) (1)
Platelets revisited. (1982) (1)
Complement activation, fibrinolysis, and nonmammalian blood coagulation factors and inhibitors (1993) (1)
What are the abnormal thrombotic responses in the clotting system of individuals with atherosclerosis? Are these responses genetically determined or adaptations to the disease state? (1992) (1)
Chapter 2A Nonenzymatic cofactors: factor V* (1986) (1)
A thrombin mediated endothelial cell dependent mechanism for factor Va inactivation (1998) (1)
Overview and research opportunities (1992) (1)
A radioimmunoassay useful for quantitating megakaryocyte growth in vitro. (1986) (1)
Recommendations on nomenclature and standards for bone proteins and growth factors. (1986) (1)
Interaction of Factor V and Factor Va with Platelets (1979) (1)
Contribution of a platelet component to endothelial prostacyclin production despite inhibition of platelet cyclooxygenase activity. (1982) (1)
Mann for the treatment of hemophilia A by factor VIIa Inhibition of thrombin generation by the zymogen factor VII : implications (2000) (1)
Predicting Thrombosis in Factor V Leiden Heterozygotes. (2008) (1)
RAPID COMMUNICATION Factor V Quebec Revisited (2016) (0)
Activated Protein C-Resistance Induced by a Low Molecular Weight Inhibitor. (2005) (0)
Erythrocyte Participation in Thrombin Generation (2011) (0)
The Effect Of Physiological Metal Ions On The Procoagulant Enzyme-Cofactor Complexes Of The Extrinsic Pathway Of Coagulation (2013) (0)
Tissue factor pathway to thrombin The hemostatic vortex (1992) (0)
Thrombin Generation in a Reconstituted System: A Reply (2002) (0)
Cleavage of Factor Va Heavy Chain at Arg643 by Thrombin Partially Inactivates the Cofactor. (2006) (0)
Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir (2021) (0)
Thrombosis: diagnosis and prophylaxis 1997. (1998) (0)
The Influence of Purified Factor V, Factor Va, and Activated Platelets on the Factor Xa Catalyzed Activation of Prothrombin (1979) (0)
StudiesontheMeasurement of ProteinS in Plasma (1991) (0)
Microsoft Word-JBC_resubmission_09-14-12.docx (2012) (0)
The Interchangeability of Viscoelastographic Instruments and Reagents (2014) (0)
Multiple Active Forms of Thrombin III . POLYPEPTIDE (2002) (0)
Purification of Ristocetin Willebrand Factor (RWF) (1975) (0)
The Coagulant Active Phospholipid(Pl) Content Of Prothrombin Complex Concentrates(Pcc) Is A Critical Determinant Of Their In Vivo Thrombogenicity (1981) (0)
Megakaryocyte growth supporting activity in human plasma (1986) (0)
Proceedings: Human prothrombin activation products. (1975) (0)
The Impact of Recombinant Technologies in Understanding Plasma Proteins Important for Hemostasis and Thrombosis (1991) (0)
Isolation of functional human coag hybridoma antibody (monoclonal antibody/affinity chromatography/Factor V activation/l (2016) (0)
Mueller et al TIMI II Subgroup Analyses : Predictors of Early Events 1255 factors for early death in patients with AMI treated with thrombolytic therapy . The Thrombolysis in Myocardial Infarction ( TIMI ) phase (2005) (0)
THROMBIN GENERATION PROFILES IN PATIENTS WITH ACUTE CORONARY SYNDROME AND STABLE CORONARY ARTERY DISEASE: A COMPUTATIONAL ANALYSIS (2007) (0)
Thrombosis and Inflammation in Acute Coronary Syndromes (2015) (0)
Histone H4-Induced Thrombin Generation in Fresh and "Reconstituted" Blood (2015) (0)
Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role? (2022) (0)
Visiting scientist program of the American Heart Association Council on thrombosis and the Burroughs Wellcome Corporation (1990) (0)
To the editor : Analyses of protein S function (0)
Proceedings of the National Heart, Lung, and Blood Institute Workshop on Hemostasis, Thrombosis, and Cardiovascular Diseases. Overview and research opportunities. (1992) (0)
Thrombosis: theoretical ,2 (1997) (0)
Thrombin (2019) (0)
Human D-Phe-Pro-Arg-CH2-alpha-thrombin crystallization and diffraction data. (1989) (0)
Quantitative Evaluation of Factor VIII in Factor VIII Products. (2004) (0)
radioimmunoassay Quantitation of human in vitro megakaryocytopoiesis by (2011) (0)
Human cerebral microvascular endothelium (CM) respond to α-thrombin by upregulating anti- and profibrinolytic protein synthesis at different times (1994) (0)
A unique response of human cerebral microvascular endothelial cells to α-thrombin (1994) (0)
Two-Dimensional Electrophoretic “Mapping” of Human Platelet Membrane Proteins (1977) (0)
[Blood coagulation]. (1952) (0)
Epitope mapping of two monoclonal antibodies to the central portion of human osteonectin (1991) (0)
History of Discovery Taking the Thrombin "Fork" (2010) (0)
Tissue Factor Plasma Analysis (2006) (0)
Bone Turnover Assessment Using Bone-Specific Biochemical Markers (1986) (0)
A Novel Ex Vivo Pressure-Induced Model for the Examination of Human Thoracic Aortic Aneurysms (2010) (0)
Proceedings: Purification of ristocetin Willebrand factor (RWF). (1975) (0)
Bone pre-treatment cells: compositions and methods (1995) (0)
The regulation of coagulation : proceedings of the International Workshop on Regulation of Coagulation, the University of Oklahoma, Norman, Oklahoma, U.S.A., September 4-8, 1979 (1980) (0)
Plasma Procofactor Activation by Factor Xla (2008) (0)
Assessing Factor V Antigen and Degradation Products in Burn and Trauma Patients. (2022) (0)
Crystal Structure of Bovine Factor Vai (2004) (0)
Nomenclature recommendations: Bone proteins and growth factors. (1986) (0)
Phospholipid-binding antibodies and thrombosis. Diagnostica Stago International Symposium, Paris, 14 May 1993. (1993) (0)
Recombinant Tissue Factor Carbohydrates and Activity of Natural and Enzyme Catalysis and Regulation (2010) (0)
on a National Heart, Lung and Blood Institute Working Group Guided Antithrombotic Therapy: Current Status and Future Research Direction: Report (2014) (0)
A process for the preparation of an agent for hemostasis. (1986) (0)
strictly antiplatelet actions Antithrombotic properties of aspirin and resistance to aspirin: beyond (2011) (0)
Trauma and Hemorrhage: Functional Characterization of Acute Traumatic Coagulopathy (2014) (0)
Factor V. (1993) (0)
Profiling trauma induced coagulopathic states (2013) (0)
Humanplatelets contain andsecrete osteonectin, amajorprotein ofmineralized bone (1986) (0)
The Resusciatative Fluid You Chose May Potentiate Bleeding. (2004) (0)
electron microscopy Studies on the structure of bovine factor V by scanning transmission (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth G. Shelburne Mann?

Kenneth G. Shelburne Mann is affiliated with the following schools:

Kenneth G. Shelburne Mann's Academic­Influence.com Rankings

Why Is Kenneth G. Shelburne Mann Influential?

Kenneth G. Shelburne Mann's Published Works

Published Works

What Schools Are Affiliated With Kenneth G. Shelburne Mann?

Kenneth G. Shelburne Mann's AcademicInfluence.com Rankings